PIDDosome expression and the role of caspase-2 activation for chemotherapy-induced apoptosis in RCCs

Cellular Oncology

Volumn 32, Issue 1-2, 2010, Pages 29-42

  Heikaus, Sebastian ^a   Pejin, Igor ^a   Gabbert, Helmut Erich ^a   Ramp, Uwe ^a   Mahotka, Csaba ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

BCL 2; Caspase 2; HA14 1; PIDD; PIDDosome; RAIDD; Renal cell carcinoma

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; CASPASE 2; CRADD PROTEIN; MESSENGER RNA; PIDD PROTEIN; PIDDOSOME PROTEIN; PROTEIN; PROTEIN BCL 2; RNA; TOPOTECAN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; CARCINOMA, RENAL CELL; CARRIER PROTEINS; CASPASE 2; CELL LINE, TUMOR; CRADD SIGNALING ADAPTOR PROTEIN; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; TOPOTECAN; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 77749242461     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: 10.3233/CLO-2009-0492     Document Type: Article

References (44)

1. C.D. Gerharz, U. Ramp, M. Dejosez, C. Mahotka, B. Czarnotta, U. Bretschneider, I. Lorenz, M. Muller, P.H. Krammer and H.E. Gabbert, Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: an important factor for evasion from negative growth control, Laboratory Investigation 79 (1999), 1521-1534.
2. U. Ramp, M. Dejosez, C. Mahotka, B. Czarnotta, T. Kalinski, M. Wenzel, I. Lorenz, M. Muller, P. Krammer, H.E. Gabbert and C.D. Gerharz, Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma, British Journal of Cancer 82 (2000), 1851-1859.
3. G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Staroslawska, J. Sosman, D. McDermott, I. Bo-drogi, Z. Kovacevic, V. Lesovoy, I.G. Schmidt-Wolf, O. Bar-barash, E. Gokmen, T. O'Toole, S. Lustgarten, L. Moore and R.J. Motzer, Global ARCC trial, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, New England Journal of Medicine 356 (2007), 2271-2281. (Pubitemid 46849157)
4. U. Ramp, T. Krieg, E. Caliskan, C. Mahotka, T. Ebert, R. Willers, H.E. Gabbert and C.D. Gerharz, XIAP expression is an independent prognostic marker in clear-cell renal carcinomas, Human Pathology 35 (2004), 1022-1028.
5. S.G. Cho and E.J. Choi, Apoptotic signaling pathways: cas-pases and stress-activated protein kinases, Journal of Biochemistry and Molecular Biology 35 (2002), 24-27.
6. S. Wang and W.S. El-Deiry, TRAIL and apoptosis induction by TNF-family death receptors, Oncogene 22 (2003), 8628-8633.
7. A. Tinel and J. Tschopp, The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress, Science 304 (2004), 843-846.
8. C.F. Lin, C.L. Chen, W.T. Chang, M.S. Jan, L.J. Hsu, R.H. Wu, M.J. Tang, W.C. Chang and Y.S. Lin, Sequential caspase-2 and caspase-8 activation upstream of mitochondria during ceramide and etoposide-induced apoptosis, Journal of Biological Chemistry 279 (2004), 40755-40761.
9. B. Zhivotovsky and S. Orrenius, Caspase-2 function in response to DNA damage, Biochemical and Biophysical Research Communications 331 (2005), 859-867.
10. S. Shin, Y. Lee, W. Kim, H. Ko, H. Choi and K. Kim, Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8, EMBO Journal 24 (2005), 3532-3542.
11. A.K. Samraj, D. Sohn, K. Schulze-Osthoff and I. Schmitz, Loss of caspase-9 reveals its essential role for caspase-2 activation and mitochondrial membrane depolarization, Molecular Biology of the Cell 18 (2007), 84-93.
12. L. Xerri, E. Devilard, C. Ayello, P. Brousset, J.C. Reed, J.F. Emile, J. Hassoun, S. Parmentier and F. Birg, Cysteine protease CPP32, but not Ich1-L, is expressed in germinal center B cells and their neoplastic counterparts, Human Pathology 28 (1997), 912-921.
13. Z. Estrov, P.F. Thall, M. Talpaz, E.H. Estey, H.M. Kantarjian, M. Andreeff, D. Harris, Q. Van, M. Walterscheid and S.M. Ko-rnblau, Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia, Blood 92 (1998), 3090-3097.
14. P. Hantschmann and R. Kürzl, Regulation of apoptosis in squa-mous cell carcinoma of the vulva, The Journal of Reproductive Medicine 45 (2000), 633-642. (Pubitemid 30661120)
15. N.J. Yoo, J.W. Lee, Y.J. Kim, Y.H. Soung, S.Y. Kim, S.W. Nam, W.S. Park, J.Y. Lee and S.H. Lee, Loss of caspase-2,-6 and-7 expression in gastric cancers, APMIS 112 (2004), 330-335.
16. A. Holleman, M.L. den Boer, K.M. Kazemier, H.B. Bever-loo, A.R. von Bergh, G.E. Janka-Schaub and R. Pieters, Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia, Blood 106 (2005), 1817-1823.
17. V.M. Zohrabian, H. Nandu, N. Gulati, G. Khitrov, C. Zhao, A. Mohan, J. Demattia, A. Braun, K. Das, R. Murali and M. Jhanwar-Uniyal, Gene expression profiling of metastatic brain cancer, Oncology Reports 18 (2007), 321-328.
18. S. Cuenin, A. Tinel, S. Janssens and J. Tschopp, p53-induced protein with a death domain (PIDD) isoforms differentially activate nuclear factor-kappaB and caspase-2 in response to geno-toxic stress, Oncogene 27 (2008), 387-396.
19. A. Tinel, S. Janssens, S. Lippens, S. Cuenin, E. Logette, B. Jac-card, M. Quadroni and J. Tschopp, Autoproteolysis of PIDD marks the bifurcation between pro-death caspase-2 and pro-survival NF-kappaB pathway, EMBO Journal 26 (2007), 197-208.
20. G. Bradley, S. Tremblay, J. Irish, C. MacMillan, G. Baker, P. Gullane and S. Benchimol, The expression of p53-induced protein with death domain (Pidd) and apoptosis in oral squa-mous cell carcinoma, British Journal of Cancer 96 (2007), 1425-1432.
21. W.K. Hofmann, S. de Vos, K. Tsukasaki, W. Wachsman, G.S. Pinkus, J.W. Said and H.P. Koeffler, Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide mi-croarray, Blood 98 (2001), 787-794.
22. L. Wang, M. Miura, L. Bergeron, H. Zhu and J. Yuan, Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death, Cell 78 (1994), 739-750.
23. E. Logette, A. Wotawa, S. Solier, L. Desoche, E. Solary and L. Corcos, The human caspase-2 gene: alternative promoters, pre-mRNA splicing and AUG usage direct isoform-specific expression, Oncogene 22 (2003), 935-946.
24. S. Solier, A. Lansiaux, E. Logette, J. Wu, J. Soret, J. Tazi, C. Bailly, L. Desoche, E. Solary and L. Corcos, Topoiso-merase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells, Molecular Cancer Resarch 2 (2004), 53-61.
25. N. Droin, C. Rébé, F. Bichat, A. Hammann, R. Bertrand and E. Solary, Modulation of apoptosis by procaspase-2 short iso-form: selective inhibition of chromatin condensation, apoptotic body formation and phosphatidylserine externalization, Onco-gene 20 (2001), 260-269.
26. S. Solier, E. Logette, L. Desoche, E. Solary and L. Corcos, Nonsense-mediated mRNA decay among human caspases: the caspase-2S putative protein is encoded by an extremely shortlived mRNA, Cell Death and Differentiation 12 (2005), 687-689.
27. W. Martinet, M.W. Knaapen, G.R. De Meyer, A.G. Herman and M.M. Kockx, Overexpression of the anti-apoptotic caspase-2 short isoform in macrophage-derived foam cells of human atherosclerotic plaques, American Journal of Pathology 162 (2003), 731-736.
28. R.J. Youle and A. Strasser, The BCL-2 protein family: opposing activities that mediate cell death, Nature Reviews Molecular Cell Biology 9 (2008), 47-59.
29. C.F. Lin, C.L. Chen, W.T. Chang, M.S. Jan, L.J. Hsu, R.H. Wu, Y.T. Fang, M.J. Tang, W.C. Chang and Y.S. Lin, Bcl-2 rescues ceramide-and etoposide-induced mitochondrial apoptosis through blockage of caspase-2 activation, Journal of Biological Chemistry 280 (2005), 23758-23765.
30. N.B. Phuoc, H. Ehara, T. Gotoh, M. Nakano, S. Yokoi, T. Deguchi and Y. Hirose, Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma, Urology 69 (2007), 843-848.
31. T. Itoi, K. Yamana, V. Bilim, K. Takahashi, F. Tomita, Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients, British Journal of Cancer 90 (2004), 200-205.
32. T. Sejima and I. Miyagawa, Expression of bcl-2, p53 oncopro-tein, and proliferating cell nuclear antigen in renal cell carcinoma, European Urology 35 (1999), 242-248.
33. G. Hofmockel, A. Wittmann, J. Dammrich and I.D. Bassukas, Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance, Anti-cancer Research 16 (1996), 3807-3811. (Pubitemid 27085053)
34. P. Lipponen, M. Eskelinen and K. Syrjänen, Expression of tumour-suppressor gene Rb, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma, British Journal of Cancer 71 (1995), 863-867.
35. M. Déjosez, U. Ramp, C. Mahotka, A. Krieg, H. Walczak, H.E. Gabbert and C.D. Gerharz, Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan, Cell Death and Differentiation 7 (2000), 1127-1136.
36. U. Ramp, C. Mahotka, T. Kalinski, E. Ebel, H.E. Gabbert and C.D. Gerharz, Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types, Anticancer Research 21 (2001), 3509-3517.
37. S. Heikaus, L. van den Berg, T. Kempf, C. Mahotka, H.E. Gab-bert and U. Ramp, HA14-1 is able to reconstitute the impaired mitochondrial pathway of apoptosis in renal cell carcinoma cell lines, Cellular Oncology 30 (2008), 419-433.
38. S.A. Fuhrman, L.C. Lasky and C. Limas, Prognostic significance of morphologic parameters in renal cell carcinoma, American Journal of Surgical Pathology 6 (1982), 655-663.
39. C.D. Gerharz, R. Moll, S. Storkel, U. Ramp, W. Thoenes and H.E. Gabbert, Ultrastructural appearance and cytoskeletal architecture of the clear, chromophilic, and chromophobe types of human renal cell carcinoma in vitro, American Journal of Pathology 142 (1993), 851-859.
40. C.D. Gerharz, U. Ramp, J. Olert, R. Moll, S. Storkel, N. Marx and H.E. Gabbert, Cytomorphological, cytogenetic, and molecular biological characterization of four new human renal carcinoma cell lines of the clear cell type, Virchows Archiv 424 (1994), 403-409.
41. S. Heikaus, T. Kempf, C. Mahotka, H.E. Gabbert and U. Ramp, Caspase-8 and its inhibitors in RCCs in vivo: the prominent role of ARC, Apoptosis 13 (2008), 938-949.
42. K. Davidson, C. Percy, A.J. Rennick, B.K. Pat, J. Li, D. Nicol, D.W. Johnson and G.C. Gobe, Comparative analysis of cas-pase activation and apoptosis in renal tubular epithelial cells and renal cell carcinomas, Nephron Experimental Nephrology 99 (2005), e112-e120.
43. J.M. Doshi, D. Tian and C. Xing, Ethyl-2-amino-6-bromo-4-(1-cyano-2- ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), a prototype small-molecule antagonist against anti-apoptotic Bcl-2 proteins, decomposes to generate reactive oxygen species that induce apoptosis, Molecular Pharmacology 4 (2007), 919-928.
44. C.T. Lee, E.M. Genega, B. Hutchinson, P.A. Fearn, M.W. Kat-tan, P. Russo and V.E. Reuter, Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors, Urologic Oncology 21 (2003), 179-184.